title: Mycelial Extract of Phellinus linteus Induces Cell Death in A549 Lung Cancer Cells and Elevation of Nitric Oxide in Raw 264.7 Macrophage Cells.
abstract: In the present study, in order to investigate the anti-proliferative phenomenon of PLME, the effects of mycelial extract of Phellinus linteus (PLME) on the growth of human lung carcinoma cell line A549 was examined. We studied on the effects of PLME on the release of nitric oxide (NO) in mouse macrophage Raw 264.7 cells. Treatment of PLME to A549 cells resulted in the growth inhibition, morphological change and induction of apoptotic cell death in a dose-dependent manner as measured by MTT assay. We found that PLME stimulated a dose-dependent increase in NO production. These findings suggest that PLME enhances the anti-tumoral activity of macrophage and may be a potential therapeutic agent for the control of human lung carcinoma cells.
authors.affiliation: Department of Bioscience & Biotechnology, Central Research Center, Whanin Pharm. Co., Ltd., 150, Sinsohyun-Dong, Ansung, Kyunggido, Korea.
authors.forename: Jong-Jin
authors.initials: JJ
authors.lastname: Lee
authors.forename: Ho-Kyun
authors.initials: HK
authors.lastname: Kwon
authors.forename: Dong-Soo
authors.initials: DS
authors.lastname: Lee
authors.forename: Seung-Woo
authors.initials: SW
authors.lastname: Lee
authors.forename: Kye-Kwan
authors.initials: KK
authors.lastname: Lee
authors.forename: Kyu-Joong
authors.initials: KJ
authors.lastname: Kim
authors.forename: Jong-Lae
authors.initials: JL
authors.lastname: Kim
keywords: A549; Nitric oxide; PLME; Phellinus linteus; Raw 264.7
references.citation: Free Radic Biol Med. 1999 Apr;26(7-8):925-35
references.pmid: 10232836
references.citation: Endocr Rev. 1996 Feb;17(1):64-102
references.pmid: 8641224
references.citation: Yakugaku Zasshi. 2005 Jul;125(7):587-91
references.pmid: 15997216
references.citation: Br J Cancer. 2006 Aug 7;95(3):282-8
references.pmid: 16868541
references.citation: N Engl J Med. 2002 Jan 10;346(2):92-8
references.pmid: 11784875
references.citation: Appl Microbiol Biotechnol. 2002 Nov;60(3):258-74
references.pmid: 12436306
references.citation: Res Immunol. 1993 May;144(4):274-6
references.pmid: 8378595
references.citation: J Immunol. 1992 Sep 15;149(6):2114-22
references.pmid: 1325525
references.citation: JAMA. 1998 Nov 11;280(18):1569-75
references.pmid: 9820257
references.citation: J Clin Oncol. 2000 Feb;18(3):623-31
references.pmid: 10653877
references.citation: Immunopharmacology. 1999 Feb;41(2):157-64
references.pmid: 10102797
references.citation: Pharmacol Rev. 1991 Jun;43(2):109-42
references.pmid: 1852778
references.citation: Res Immunol. 1993 May;144(4):284-7; discussion 294-8
references.pmid: 8378598
references.citation: Ann Intern Med. 1994 Feb 1;120(3):227-37
references.pmid: 8273987
references.citation: J Immunol Methods. 1984 Mar 30;68(1-2):167-75
references.pmid: 6707477
references.citation: J Biol Chem. 1993 Jan 25;268(3):1908-13
references.pmid: 7678412
references.citation: J Clin Oncol. 1999 Jan;17(1):12-8
references.pmid: 10458212
references.citation: J Exp Med. 1989 May 1;169(5):1543-55
references.pmid: 2497225
references.citation: Chest. 1997 Jun;111(6):1710-7
references.pmid: 9187198